Zacks Small Cap Research on MSN2mon
RANI: New Triagonist Data in Weight Loss
The molecule contains GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. It was administered ...
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today ...
Nature29d
Pairing up with GLP-1 to combat obesity
Glucagon-like peptide 1 receptor agonists ... combine the beneficial effects of two or more hormones into a single molecule — are being explored, with a dual GLP-1R/ gastric inhibitory ...
Medscape10d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
BioWorld29d
Structure Therapeutics selects lead oral DACRA for obesity
Structure Therapeutics Inc. has selected a lead oral small-molecule amylin receptor agonist ... that is being evaluated for use either alone or in combination with glucagon-like peptide-1 (GLP-1) ...
BioWorld29d
Merck & Co. signs license agreement for Hansoh Pharma GLP-1 receptor agonist
Merck & Co. Inc. and Hansoh Pharmaceutical Group Co. Ltd. have entered into an exclusive global license agreement for HS-10535, a preclinical oral small-molecule glucagon-like peptide-1 (GLP-1) ...